Nicox S.A. (EPA:ALCOX)

Market Cap	38.27M
Revenue (ttm)	3.57M
Net Income (ttm)	-17.36M
Shares Out	72.20M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	8.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	792,509
Average Volume	2,178,048
Open	0.5500
Previous Close	0.5300
Day's Range	0.5310 - 0.5660
52-Week Range	0.1400 - 0.6500
Beta	0.80
RSI	68.31
Earnings Date	Jul 18, 2025

About Heartland Financial USA

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2022, Nicox's revenue was 3.27 million, a decrease of -54.78% compared to the previous year's 7.23 million. Losses were -27.76 million, -36.57% less than in 2021.